Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Chief Financial Officer Sachin Mehra said Mastercard is seeing a "strong consumer," which he attributed to factors such as low unemployment, high wages and the wealth effect. Spending has been healthy ...

Move over Humira, Skyrizi and Rinvoq are expected to beat the former megablockbuster’s peak sales by the end of this year.

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Mastercard shares are up about 6% so far this year, which Jeffrey flagged was about 5 percentage points behind Visa's stock gain. "We contend that a strong global economy will power a catch-up trade," ...

Meta's strong earnings report sent its stock soaring after hours. The company also made it clear that the AI talent wars come ...

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

As previously reported, William Blair downgraded NeoGenomics (NEO) to Market Perform from Outperform after the company reported Q2 results and cut ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...